Abstract
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Alkylating / administration & dosage*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / pathology
-
Brain Neoplasms / radiotherapy*
-
Chemotherapy, Adjuvant
-
Combined Modality Therapy
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives*
-
Female
-
Glioblastoma / drug therapy
-
Glioblastoma / pathology
-
Glioblastoma / radiotherapy*
-
Humans
-
Male
-
Middle Aged
-
Necrosis
-
Radiation-Sensitizing Agents / administration & dosage*
-
Radiotherapy Dosage
-
Temozolomide
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Radiation-Sensitizing Agents
-
Dacarbazine
-
Temozolomide